J&J(US:JNJ) Yahoo Finance·2026-01-16 19:17Company Overview - Johnson & Johnson (NYSE: JNJ) is recognized as one of the most profitable US stocks to buy, with a focus on innovative medicines and medical technologies [1][4] - The company has a diverse clientele, including retailers, wholesalers, healthcare professionals, and hospitals [4] Price Target Adjustments - Bernstein raised the price target for Johnson & Johnson to $208 from $193 while maintaining a 'Market Perform' rating [1] - Stifel also increased its price target for Johnson & Johnson to $205 from $190, keeping a 'Hold' rating [3] Recent Acquisitions - Johnson & Johnson completed the acquisition of Halda Therapeutics for approximately $3.05 billion on December 29, 2025 [3] - The Halda acquisition is expected to be dilutive to Johnson & Johnson's adjusted earnings per share by a total of $0.20, impacting $0.10 in both 2025 and 2026 [4] Market Performance and Outlook - U.S. healthcare stocks, including Johnson & Johnson, have shown improved performance following a low point in September 2025, with a more favorable outlook for 2026 [2]